Karolinska Development announces outcome of the rights

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Karolinska Development announces outcome of the rights issue of convertibles

Not for publication or distribution, in whole or in part, in or into the United States, Canada, Australia, Hong Kong, South Africa, New Zealand or Japan.

STOCKHOLM - 30 December 2014. Karolinska Development AB today announces that the company has concluded the rights issue of convertibles which preliminary has been subscribed to approximately 77 percent. The rights issue, together with the directed issue of convertibles to Thai Charoen Pokphand Group (“CP Group”)1, will provide Karolinska Development with preliminary proceeds of approximately SEK 347.9 million before transaction costs.

Through the issues of convertibles, Karolinska Development issues:

  • a convertible loan with a nominal amount of preliminary SEK 175,000,880.98 through a rights issue of convertibles, and
  • a convertible loan with a nominal amount of SEK 172,858,294.11 through a directed issue of convertibles to CP Group.

The rights issue of convertibles with preferential rights for the company’s shareholders was preliminary subscribed for with support of subscription rights to approximately 32 percent. Additionally, CP Group, in accordance with their guarantee undertaking, subscribed for the full guarantee amount of SEK 100 million which corresponds to approximately 44 percent of the rights issue amount. In addition, applications to subscribe for convertibles without support of subscription rights corresponding to approximately one (1) percent of the rights issue were received. Altogether this means that the rights issue with preferential rights for the company’s shareholders is preliminary subscribed to approximately 77 percent.

Allotment is done in accordance with the allotment principles stated in the prospectus. Notification of any allotment of subscription without preferential rights will be provided through distribution of a settlement note. Payment shall be made in accordance with the instructions on the settlement note. The notification of allotment will only be issued to those who have been allotted convertibles.

In the directed issue of convertibles to CP Group totaling SEK 172,858,294.11, approximately SEK 23 million has already been received and furthermore a confirmation of the transfer has been received for the remainder of the amount corresponding to SEK 150 million.

The convertibles fall due for payment on 31 December 2019, given that conversion has not taken place before that, and carries an annual interest of eight (8) percent. The interest is capitalized annually in arrears and is payable in connection with the repayment of the convertibles on the maturity date, provided that conversion has not taken place before that. Conversion into shares of series B can take place from the date when the issues are registered with the Swedish Companies Registration Office, until 30 June 2019 at a conversion price of SEK 22. At full conversion, and provided that all convertibles are converted on the last date of conversion, the number of shares of series B in Karolinska Development will increase by 21,941,987, which implies a dilution of approximately 29 percent.

Last day of trading in the paid subscribed convertibles (BTU) is expected to be 13 January 2015. The BTUs will be replaced with convertibles as soon as the issues of convertibles are registered with the Swedish Companies Registration Office, which is expected to take place on 15 January 2015. Thereafter Karolinska Development expects that the convertibles will be subject to trade on Nasdaq Stockholm. If the application for admission to trading of the convertibles is rejected, Karolinska Development may consider having the convertibles be subject to trading on First North or another alternative marketplace. Note that there will be no trading in BTUs or convertibles from 14 January 2015 until and including 15 January 2015 in order to effect the conversion of BTUs into convertibles.

Financial and legal advisor Danske Bank A/S, Danmark, Sverige Filial is acting as financial advisor and Roschier Advokatbyrå AB is acting as legal advisor to Karolinska Development in connection with the issues of convertibles.

 1”CP Group”, in this press release, is used to describe the units included in Thai Charoen Pokphand Group

 

For further information, please contact: Bruno Lucidi, CEO, Karolinska Development AB Phone: +46 (0) 8 524 860 70, e-mail: bruno.lucidi@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB Phone: +46 (0) 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

 

 

TO THE EDITORS

About Karolinska Development AB Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. For more information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on Nasdaq Stockholm (KDEV). Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.

 

IMPORTANT INFORMATION

This press release is not an offer to sell or a solicitation of any offer to buy any securities issued by Karolinska Development AB (publ) (the "Company") in any jurisdiction.

Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. 

In the United Kingdom, this announcement and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this announcement relates is available only to, and will be engaged in only with, “qualified investors” (as defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). Persons who are not relevant persons should not take any action on the basis of this announcement and should not act or rely on it.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 180

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 410

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 298

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 254

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 317

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 343

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 409

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 250

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 353

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 229

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Novartis Fabhalta® Breakthrough in PNH Treatment Showcased

Updated Category News Views 290

Novartis Fabhalta® Achieves Significant Hemoglobin Improvements In recent studies, Novartis has showcased promising results from its Phase IIIB APPULSE-PNH study regarding Fabhalta (iptacopan), designed for adult patients suffering from paroxysmal nocturnal hemoglobinuria (PNH). Patients who switched from anti-C5 therapies demonstrated noteworthy improvement in their...

Continue Reading
Insights into Indonesia's Economic Landscape for Credit Investors

Updated Category News Views 208

Understanding Indonesia's Market Dynamics This week, Gimme Credit unveiled a new Indonesia Country Report that delves into the recent fluctuations in the equity market and its potential ripple effects on foreign exchange and bond markets. The inquiry raises fundamental questions about whether these shifts could necessitate a higher risk premium for those investing in...

Continue Reading
Pliant Therapeutics to Showcase Innovations at Key Healthcare Conference

Updated Category News Views 187

Introduction to Pliant Therapeutics' Participation Pliant Therapeutics, Inc. (NASDAQ: PLRX), a dedicated force in the clinical-stage biotechnology sector, is set to make waves at an upcoming healthcare conference. The event serves as a platform for the company to showcase its integrin-based therapeutics—game-changing innovations aimed at treating various serious health...

Continue Reading
OSB Group PLC Financial Performance Overview for 2025

Updated Category News Views 322

OSB Group PLC Trading Update Summary OSB GROUP PLC, a specialist lending and retail savings group, is pleased to share its trading update for the nine-month period concluding on 30 September 2025. This report highlights the Group's steady growth and enhanced financial performance in line with expectations and strategic objectives. Performance Insights for the Nine-Month...

Continue Reading
Toll Brothers Unveils Luxurious Homes at Ridge Pointe Estates

Updated Category News Views 222

Toll Brothers Unveils New Luxury Homes at Ridge Pointe Estates Toll Brothers, Inc. (NYSE: TOL), recognized as a leader in the luxury home construction industry, has introduced its latest community, Ridge Pointe Estates. This community, now officially open, offers prospective homeowners a blend of elegance and modern living. Located within a serene setting, Ridge Pointe...

Continue Reading